Mangalam Drugs And Organics profit increased 206.06% in (Q4) FY 2019-20

Source

Team Infinities:

Mangalam Drugs And Organics Limited NSE Symbol:MANGALAM, BSE Security Code:532637 has declared its 4th(fourth) quarter audited Standalone financial report from the month of January, 2020 to the month of March, 2020; for the fiscal year 2019-20.

Revenue Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current Quarter (January, 2020 - March, 2020) Previous Quarter (October, 2019 - December, 2019) Corresponding Quarter (January, 2019 - March, 2019) 12 Months Ended (April, 2019 - March, 2020) Corresponding 12 Months Ended (April, 2018 - March, 2019)
88.55 62.60 48.29 283.53 227.90
Calculated Revenue of Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current(March, 2020) VS Previous(December, 2019) Current(March, 2020) VS Corresponding(March, 2019) 12 months Ended(April, 2019 - March, 2020) VS Corresponding 12 months Ended(April, 2018 - March, 2019)
Change Change % Change Change % Change Change %
25.95 41.45%(Revenue Increase) 40.26 83.37%(Revenue Increase) 55.63 24.41%(Revenue Increase)

Revenue: Mangalam Drugs And Organics Limited's financial report shows that the company's revenue increased by 41.45% in QoQ(Quarter on Quarter) / current quarter(January, 2020 - March, 2020) for revenue increase of Rs.25.95 crores, as the company posted revenue of Rs.88.55 crores; in compare to previous quarter(October, 2019 - December, 2019) when the company reported revenue of Rs.62.60 crores.
The result also shows that the company's revenue increased by 83.37% in YoY(Year over Year) / in current quarter(January, 2020 - March, 2020) for revenue increase of Rs.40.26 crores; in compare to corresponding quarter(January, 2019 - March, 2019) when the company posted revenue of Rs.48.29 crores
The company also reported that its revenue increased by 24.41% in 12 months end(April, 2019 - March, 2020) for revenue increase of Rs.55.63 crores, since the company reported revenue of Rs.283.53 crores; in compare to corresponding 12 months end(April, 2018 - March. 2019) when the company posted revenue of Rs.227.90 crores.

Gross Margin(%) Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current Quarter (January, 2020 - March, 2020) Previous Quarter (October, 2019 - December, 2019) Corresponding Quarter (January, 2019 - March, 2019) 12 Months Ended (April, 2019 - March, 2020) Corresponding 12 Months Ended (April, 2018 - March, 2019)
52.38 46.14 18.51 43.05 19.11
Calculated Gross Margin(%) of Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current(March, 2020) VS Previous(December, 2019) Current(March, 2020) VS Corresponding(March, 2019) 12 months Ended(April, 2019 - March, 2020) VS Corresponding 12 months Ended(April, 2018 - March, 2019)
Change Change % Change Change % Change Change %
6.23 13.51%(GM Increase) 33.87 182.97%(GM Increase) 23.94 125.30%(GM Increase)

Gross Margin(%)/ GM: The company's financial report indicates, the company's GM increased by 13.51% in QoQ(Quarter on Quarter) / current quarter(January, 2020 - March, 2020) for 6.23% GM increase, as the company reported 52.38% GM; in compare to previous quarter(October, 2019 - December, 2019) when the company reported 46.14% GM.
The result also indicates, the company's GM increased by 182.97% in YoY(Year over Year) / in current quarter(January, 2020 - March, 2020) for 33.87% GM increase; in compare to corresponding quarter(January, 2019 - March, 2019) when the company reported 18.51% GM.
The company also reported that its GM increased by 125.30% in 12 months end(April, 2019 - March, 2020) for 23.94% GM increase, since the company reported 43.05% GM; in compare to corresponding 12 months end(April, 2018 - March. 2019) when the company reported 19.11% GM.

EBITDA Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current Quarter (January, 2020 - March, 2020) Previous Quarter (October, 2019 - December, 2019) Corresponding Quarter (January, 2019 - March, 2019) 12 Months Ended (April, 2019 - March, 2020) Corresponding 12 Months Ended (April, 2018 - March, 2019)
7.61 5.61 0.47 24.87 10.00
Calculated EBITDA of Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current(March, 2020) VS Previous(December, 2019) Current(March, 2020) VS Corresponding(March, 2019) 12 months Ended(April, 2019 - March, 2020) VS Corresponding 12 months Ended(April, 2018 - March, 2019)
Change Change % Change Change % Change Change %
2.00 35.65%(EBITDA Increase) 7.14 1519.15%(EBITDA Increase) 14.87 148.70%(EBITDA Increase)

EBITDA/ Earnings before interest, tax, depreciation and amortization: The company's financial report shows that the company's EBITDA increased by 35.65% in QoQ(Quarter on Quarter) / current quarter(January, 2020 - March, 2020) for EBITDA increase of Rs.2.00 crores, as the company posted EBITDA of Rs.7.61 crores; in compare to previous quarter(October, 2019 - December, 2019) when the company reported EBITDA of Rs.5.61 crores.
The result also shows that the company's EBITDA increased by 1519.15% in YoY(Year over Year) / in current quarter(January, 2020 - March, 2020) for EBITDA increase of Rs.7.14 crores; in compare to corresponding quarter(January, 2019 - March, 2019) when the company posted EBITDA of Rs.0.47 crore
The company also reported that its EBITDA increased by 148.70% in 12 months end(April, 2019 - March, 2020) for EBITDA increase of Rs.14.87 crores, since the company reported EBITDA of Rs.24.87 crores; in compare to corresponding 12 months end(April, 2018 - March. 2019) when the company posted EBITDA of Rs.10.00 crores.

Profit and Loss Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current Quarter (January, 2020 - March, 2020) Previous Quarter (October, 2019 - December, 2019) Corresponding Quarter (January, 2019 - March, 2019) 12 Months Ended (April, 2019 - March, 2020) Corresponding 12 Months Ended (April, 2018 - March, 2019)
5.05(Profit ) 1.65(Profit ) 6.01(Loss ) 8.25(Profit ) 8.03(Loss )
Calculated Profit and Loss of Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current(March, 2020) VS Previous(December, 2019) Current(March, 2020) VS Corresponding(March, 2019) 12 months Ended(April, 2019 - March, 2020) VS Corresponding 12 months Ended(April, 2018 - March, 2019)
Change Change % Change Change % Change Change %
3.40 206.06%(Profit Increase) 11.06 184.03%(Profit Increase) 16.28 202.74%(Profit Increase)

Profit and Loss / PAT(Profit after Tax): The company's financial report shows that the company's profit increased by 206.06% in QoQ(Quarter on Quarter) / current quarter(January, 2020 - March, 2020) for profit increase of Rs.3.40 crores, as the company posted profit of Rs.5.05 crores; in compare to previous quarter(October, 2019 - December, 2019) when the company reported profit of Rs.1.65 crores.
The result also shows that the company's profit increased by 184.03% in YoY(Year over Year) / in current quarter(January, 2020 - March, 2020) for profit increase of Rs.11.06 crores; in compare to corresponding quarter(January, 2019 - March, 2019) when the company posted loss of Rs.6.01 crores
The company also reported that its profit increased by 202.74% in 12 months end(April, 2019 - March, 2020) for profit increase of Rs.16.28 crores, since the company reported profit of Rs.8.25 crores; in compare to corresponding 12 months end(April, 2018 - March. 2019) when the company posted loss of Rs.8.03 crores.

EPS Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current Quarter (January, 2020 - March, 2020) Previous Quarter (October, 2019 - December, 2019) Corresponding Quarter (January, 2019 - March, 2019) 12 Months Ended (April, 2019 - March, 2020) Corresponding 12 Months Ended (April, 2018 - March, 2019)
3.19 1.04 3.80(Negative) 5.21 5.07(Negative)
Calculated EPS of Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Current(March, 2020) VS Previous(December, 2019) Current(March, 2020) VS Corresponding(March, 2019) 12 months Ended(April, 2019 - March, 2020) VS Corresponding 12 months Ended(April, 2018 - March, 2019)
Change Change % Change Change % Change Change %
2.15 206.73%(EPS Increase) 6.99 183.95%(EPS Increase) 10.28 202.76%(EPS Increase)

EPS /Earning per Share: The company's financial report shows that the company's EPS increased by 206.73% in QoQ(Quarter on Quarter) / current quarter(January, 2020 - March, 2020) for EPS increase of Rs.2.15, as the company posted EPS of Rs.3.19; in compare to previous quarter(October, 2019 - December, 2019) when the company reported EPS of Rs.1.04.
The result also shows that the company's EPS increased by 183.95% in YoY(Year over Year) / in current quarter(January, 2020 - March, 2020) for EPS increase of Rs.6.99; in compare to corresponding quarter(January, 2019 - March, 2019) when the company posted Negative EPS of Rs.3.80
The company also reported that its EPS increased by 202.76% in 12 months end(April, 2019 - March, 2020) for EPS increase of Rs.10.28, since the company reported EPS of Rs.5.21; in compare to corresponding 12 months end(April, 2018 - March. 2019) when the company posted Negative EPS of Rs.5.07.

Assets Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Details Non-current Assets Current Assets
Current Quarter(March, 2020) Previous Year End(March, 2019) Current Quarter(March, 2020) Previous Year End(March, 2019)
Reported 111.49 106.32 119.17 105.04
  Change Change % Change Change %
Calculated 5.17 4.86%(Assets Increase) 14.13 13.45%(Assets Increase)

Assets:The company reported its non-current assets increased by 4.86% in current year end(March, 2020) for non-current assets increase of Rs.5.17 crores, since the company reported net non-current assets of Rs.111.49 crores; in compare to previous year end(March, 2019) when the company reported net non-current assets of Rs.106.32 crores.
The balance sheet of the company also shows that, its current assets increased by 13.45% in current year end(March, 2020) for current assets increase of Rs.14.13 crores, as the company reported net current assets of Rs.119.17 crores; against previous year end(March, 2019) when the company reported net current assets of Rs.105.04 crores.

Liabilities Reported by Mangalam Drugs And Organics Limited for Fourth Quarter FY, 2019-20
Details Non-current Liabilities Current Liabilities
Current Quarter(March, 2020) Previous Year End(March, 2019) Current Quarter(March, 2020) Previous Year End(March, 2019)
Reported 17.26 24.88 109.47 90.81
  Change Change % Change Change %
Calculated 7.62 30.63%(Liabilities Decrease) 18.66 20.55%(Liabilities Increase)

Liabilities:The company reported its non-current liabilities decreased by 30.63% in current year end(March, 2020) for non-current liabilities decrease of Rs.7.62 crores, since the company reported net non-current liabilities of Rs.17.26 crores; in compare to previous year end(March, 2019) when the company reported net non-current liabilities of Rs.24.88 crores.
The balance sheet of the company also shows that, its current liabilities increased by 20.55% in current year end(March, 2020) for current liabilities increase of Rs.18.66 crores, as the company reported net current liabilities of Rs.109.47 crores; against previous year end(March, 2019) when the company reported net current liabilities of Rs.90.81 crores.

 


***All amounts are given in Crore Indian Rupees(INR) except EPS (Earnings per share) which are in Indian Rupees(INR) only.***
Gross Margin=Total Revenue from Operations -(Cost of Materials Consumed + Purchases of stock-in-trade - Changes in inventories of finished goods, work-in-progress and stock-in-trade).
Gross Margin%=(Gross Margin / Total Revenue from Operations)*100.
EBITDA=Commission/Interest + Depreciation and Amortization + Tax + Profit/Loss (PAT).
1 Lac = 100,000.
1 Million = 10 Lacs.
1 Crore = 10 Millions.
1 Crore = 100 Lacs.
1 Billion = 1000 Millions.
1 Billion = 100 Crores.

 

Add new comment

Comment Editor

  • No HTML tags allowed.